TLSI ▲ +16.9% - TriSalus Life Sciences, Inc. $TLSI H.C. Wainwright raised the firm's price target on TriSalus Life Sciences to $12 from $11 and keeps a Buy rating on the shares. Following TriNav Advance clearance, the firm upped its liver procedure-volume growth assumptions from 2027 and beyond. H.C. Wainwright raised its price target on TriSalus Life Sciences to $12 from $11 and maintained a Buy rating, citing increased confidence in the company's growth trajectory following TriNav Advance clearance. The firm's analyst revised upward its assumptions for liver procedure-volume growth starting in 2027 and beyond, signaling stronger conviction in the company's commercial potential. The 16.9% stock gain reflects investor enthusiasm around the improved outlook and regulatory progress. 23-SEP-2026 09:12 AM ET